Anemia, Iron Deficiency Clinical Trial
Official title:
Dates a Food Treasure: Use of Dates Fruit in Alleviating and Managing Therapy-induced Anaemia for Hepatitis C Patients in Seven Villages of Egypt With Improving Their Quality of Life
Verified date | February 2020 |
Source | National Research Center, Egypt |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Introduction: In May 2016, seven villages in three governorates of Egypt were declared to be
the first villages free from hepatitis C upon eliminating HCV virus by treatment with
Sofosbuvir plus ribavirin (an interferon-free regimen). These patients were amounted to 2340
cases out of 19,991 screened residents of the seven villages within three governorates of
Egypt. Although this combination was proved effective (95 %) in treatment of HCV genotype 4
among Egyptians, yet it resulted in anaemia with decreased quality of life for the majority
of the treated HCV patients.
Aim of the project: To assess and manage therapy-induced anaemia among 2340 treated chronic
hepatitis C patients with Sofosbuvir plus ribavirin, and improving their quality of life by
provision of a comprehensive nutritional interventions that is based on Dates fruit intake.
Methodology: Dates fruit intake for all the diagnosed anaemic patients was provided for 16
weeks (four months). Five pieces of Dates fruit were taken as breakfast on daily basis (each
date fruits is about 10 -20 gm). The Dates fruit that was used was Saudi's Dates extract
known as Barni which is organic Dates. This Barni is known for its very high nutritive value
(vitamins, minerals and antioxidants) compared with other Dates types. This Dates was
imported from Saudi Arabia as donation through collaboration between NRC with Taibah
University and Sustainable Development Project in the Kingdom of Saudi Arabia (KSA). In
addition to Dates fruit intake, nutritional education to alleviate their anaemia was also
provided. Haemoglobin level, risk of malnutrition and health-related quality of life (HRQoL)
were assessed in all anemic patients before and after four months of intervention.
Status | Completed |
Enrollment | 131 |
Est. completion date | December 25, 2019 |
Est. primary completion date | July 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - therapy induced anemia (HCV treated cases with anemia) Hemoglobin lower than normal levels indicating mild and moderate anemia. The normal hemoglobin range is generally defined as 13.2 to 16.6 grams (g) of hemoglobin per deciliter (dL) of blood for men and 11.6 to 15. g/dL for women. Exclusion Criteria: - Severe anemia is manifested when HB level is less than 8 grams (g) of hemoglobin per deciliter (dL) for both adult men aged 15 years and above and non- pregnant women aged 15 years and above |
Country | Name | City | State |
---|---|---|---|
Egypt | National Research Centre | Giza | Al Jizah |
Lead Sponsor | Collaborator |
---|---|
National Research Center, Egypt | Australian Embassy of Egypt, Rotary club of Heliopolis Sporting, Egypt, Sustainable Development Project in the Kingdom of Saudi Arabia (KSA), Taibah University |
Egypt,
Al-Radadi, N.S. Green synthesis of platinum nanoparticles using Saudi's Dates extract and their usage on the cancer cell treatment. Arabian Journal of Chemistry .2019; 12, 330-349
Newby PK, Hu FB, Rimm EB, Smith-Warner SA, Feskanich D, Sampson L, Willett WC. Reproducibility and validity of the Diet Quality Index Revised as assessed by use of a food-frequency questionnaire. Am J Clin Nutr. 2003 Nov;78(5):941-9. — View Citation
Rock W, Rosenblat M, Borochov-Neori H, Volkova N, Judeinstein S, Elias M, Aviram M. Effects of date ( Phoenix dactylifera L., Medjool or Hallawi Variety) consumption by healthy subjects on serum glucose and lipid levels and on serum oxidative status: a pilot study. J Agric Food Chem. 2009 Sep 9;57(17):8010-7. doi: 10.1021/jf901559a. — View Citation
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. — View Citation
WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1)
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent change of the mean Hb level as a result of interventions | The normal hemoglobin range is generally defined as 13.2 to 16.6 grams (g) of hemoglobin per deciliter (dL) of blood for men and 11.6 to 15. g/dL for women. This is according toWorld Health Organization (WHO) for the diagnosis of anaemia and assessment of severity. Screening for anaemia by Hemo-Cue then confirmation by the automated cell counter for assessing the incidence of anaemia and measuring haemoglobin concentration (Hb) Both serum iron and ferritin level were measured for confirming the severity of anaemia; mild, moderate and severe anaemia |
Four months after the initiation of the intervention | |
Primary | percent change of the severity of anaemia | The percent change of the severity of anaemia from mild to moderate or severe and the reversed was measured as per each participants | difference from the initial (before the intervention) with that four months after the initiation of the intervention | |
Secondary | Percent change of diet quality as a result of the interventions (as measured by the Diet Quality Index (DQI) | The Diet Quality Index (DQI) is an instrument developed to measure overall diet quality that reflects a risk gradient for diet-related chronic disease. Dietary moderation and diversity are 2 new components. DQI-R scores range from 0 to 10 for each component, for a highest possible diet quality score of 100. Three levels of malnutrition were defined according to DQI : for the risk of anemia and malnutrition :At risk: below 40 Possible at risk: 40-50 Not at risk: more than 50 |
The difference from the initial (before the intervention) with that of four months after the initiation of the intervention | |
Secondary | Percent change of the Health related quality of life (HRQoL) as a result of interventions | SF-36 questionnaire for quality of life was implemented. The instrument is extensively validated and has been widely used for assessment of HRQoL in various settings including clinical trials . The questionnaire was provided in Arabic and this was done in the patients' villages. The SF-36 includes 36 questions about patients' perception of wellbeing, health status and daily functioning, which are used to calculate 8 HRQoL domain scores, each ranging from 0 to 100 with higher scores indicating better health: Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH). | The difference from the initial (before the intervention) with that of four months after the initiation of the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435574 -
Lactoferrin for Treatment of Iron Deficiency Anemia.
|
Phase 4 | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Not yet recruiting |
NCT05050851 -
Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
|
||
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04626414 -
Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Recruiting |
NCT05304442 -
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department
|
Phase 3 | |
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Completed |
NCT05047211 -
Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
|
Phase 4 | |
Not yet recruiting |
NCT06061393 -
Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia
|
Phase 4 | |
Completed |
NCT05190263 -
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
|
||
Completed |
NCT03318055 -
Prevalence of Hyperglycemia and Anaemia in Elective Surgical Patients
|
||
Completed |
NCT04631679 -
Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)
|
||
Recruiting |
NCT05225545 -
Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis
|
Phase 3 | |
Recruiting |
NCT03347513 -
Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?
|
Phase 4 | |
Recruiting |
NCT04708665 -
Iron Deficiency Anemia and Non-iron Deficiency Anemia in Pregnancy in India
|
||
Completed |
NCT02404012 -
Iron Supplement to Improve Iron Status Following Bariatric Surgery
|
N/A | |
Completed |
NCT04137354 -
Iron and Vitamin A in School Children
|
N/A | |
Not yet recruiting |
NCT06096103 -
A Clinical Study to Check the Safety and Effectiveness of Botanical Extract Standardized for Iron + Vitamin c and Botanical Extract Standardized for Iron in Adult Human Subjects With Anemia or Iron-deficiency Anemia
|
N/A | |
Completed |
NCT03156712 -
Iron Absorption From Iron-enriched Aspergillus Oryzae
|
N/A |